Clinical Trial Update: TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection [Phase 4]

View source ↗

Summary

Phase 4 trial update indicates termination of the SENSIMED Triggerfish study involving intraocular anti-VEGF injections for neovascular age-related macular dege…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration
• Open-angle Glaucoma

Snippet

Sponsor: Sensimed AG | Conditions: Neovascular Age Related Macular Degeneration (AMD), Open Angle Glaucoma | Phase 4 | Status: TERMINATED